What Is This Docket?
In late 2025, Harrison.ai (via Rubrum Advising LLC) filed a citizen petition requesting the FDA create a partial 510(k) exemption pathway for radiology AI devices — specifically Computer-Aided Detection (CADe), Diagnosis (CADx), combined (CADe/x), and Triage & Notification (CADt) devices classified under 21 CFR 892.2060, .2070, .2080, and .2090. Under the proposal, manufacturers holding at least one prior relevant 510(k) clearance could bring additional devices to market under enhanced post-market controls — without requiring a new premarket submission for each update or indication. The FDA published the petition in the Federal Register on December 29, 2025 and accepted public comments through early March 2026.
Sentiment Distribution
Support vs. Opposition by Stakeholder
Key Observations
Conditional support is the dominant position (8 of 20 submissions). Most respondents — including prominent AI developers — agree the current regulatory framework creates a measurable innovation gap, but want the exemption conditioned on demonstrated QMS maturity, post-market monitoring, and performance benchmarks.
Professional societies are aligned in opposition. ACR (40,000+ members) and RSNA (52,000+ members) both opposed the petition as written, citing inadequate post-market surveillance infrastructure and risks of AI silent failure modes. Their influence on FDA is significant.
The geographic innovation gap is well-documented. Multiple companies (Harrison.ai, AZmed, Radiobotics, Quibim) submitted direct comparisons showing their U.S.-cleared products are materially narrower than their CE-marked EU equivalents — not due to science, but regulation.
Executive Takeaways
Key strategic insights for medical device developers and executives following this docket.